Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 4 Carcinoma, Non-Small-Cell Lung 3 Head and Neck Neoplasms 2 Carcinoma, Hepatocellular 2 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1 Rectal Neoplasms 1 Prostate Adenocarcinoma 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms 1 Neoplasm, Residual 1 Nasopharyngeal Carcinoma 1 Liver Diseases 1 Liposarcoma 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 361 Trastuzumab 352 Paclitaxel 304 Docetaxel 272 Capecitabine 222 Letrozole 221 Carboplatin 185 Doxorubicin 181 Tamoxifen 157 Radiotherapy 154 Epirubicin 145 Fulvestrant 143 Anastrozole 139 Surveys and Questionnaires 133 Exercise 128 pertuzumab 113 Vinorelbine 110 Blood Specimen Collection 109 exemestane 106 palbociclib 104 Bevacizumab 104 pembrolizumab 98 Magnetic Resonance Spectroscopy 97 Albumin-Bound Paclitaxel 87 Gemcitabine 84 Drug Therapy 83 Lapatinib 78 130-nm albumin-bound paclitaxel 72 Neoadjuvant Therapy 71 Cisplatin 69

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Breast Neoplasms × Adjuvants, Pharmaceutic × Clear all

NCT05296746 2026-05-14

RIBOLARIS

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡